Financial Performance - The company's operating revenue for 2021 was approximately CNY 1.29 billion, representing a 37.99% increase compared to CNY 936.52 million in 2020[21]. - The net profit attributable to shareholders for 2021 was a loss of approximately CNY 180.12 million, a decrease of 4,417.79% compared to a profit of CNY 4.17 million in 2020[22]. - The net cash flow from operating activities for 2021 was approximately CNY 96.42 million, a significant increase of 387.10% compared to a negative cash flow of CNY 33.58 million in 2020[22]. - Total assets at the end of 2021 were approximately CNY 2.34 billion, an increase of 18.89% from CNY 1.97 billion at the end of 2020[22]. - The company's net assets attributable to shareholders decreased by 18.4% to approximately CNY 949.43 million at the end of 2021, down from CNY 1.16 billion at the end of 2020[22]. - The basic and diluted earnings per share for 2021 were both -0.37 RMB, a decrease of 4,352.87 percentage points compared to the previous year[23]. - The weighted average return on equity was -17.20%, down 17.56 percentage points from the previous year[23]. - The company reported a significant increase in cash flow from operating activities, with a net cash flow of ¥96,420,908.67, compared to a negative cash flow of ¥33,584,944.13 in the previous year, marking a 387.10% improvement[55]. - The company reported a net loss of CNY 147,629,932.28 in retained earnings, compared to a profit of CNY 42,924,427.31 in the previous year[174]. - The total comprehensive loss for 2021 was approximately -¥197.95 million, compared to a comprehensive income of ¥21.27 million in 2020[180]. Business Segments and Operations - The company operates two main business segments: health product production and sales, and health medical service management, focusing on synergistic development[45]. - The aquaculture division emphasized high-quality breeding and the development of organic fresh food products[33]. - The revenue from the aquaculture segment accounted for 58.65% of total revenue, representing a year-on-year growth of 24.36%, with frozen aquatic products sales increasing by 280.16%[35]. - The health liquor segment's revenue share was 10.86%, showing a significant year-on-year increase of 49.95%[36]. - The health medical services segment's revenue share reached 16.74%, with a remarkable year-on-year growth of 530.07%[38]. - The company is focusing on the development of a "medical, nursing, and rehabilitation" integrated model in its health medical services[38]. - The company has established partnerships with well-known medical institutions to enhance its brand influence and service quality[38]. - The company is actively pursuing a strategic transformation towards the health industry, integrating health products and services[38]. - The company has established a comprehensive freshwater fish industry chain, emphasizing quality management and obtaining multiple certifications, including ISO9001 and organic product certification[46]. Market and Competitive Landscape - The company faces various operational risks, including market competition and food safety risks, as detailed in the management discussion section[9]. - The company faces competition risks in the market for its natural fish products, which have lower yields compared to pond-raised fish[78]. - The company faces risks in the white liquor industry due to intense competition and the potential market squeeze from national brands, as its products are categorized as regional brands[79]. - The demand for high-end liquor products is increasing, with a significant shift towards premium brands due to rising consumer health awareness and disposable income[44]. - The rehabilitation medical industry in China is projected to grow rapidly, with an expected market size exceeding 220 billion yuan by 2025, reflecting a compound annual growth rate of 20.60% from 2016 to 2025[44]. Governance and Management - The company held one annual general meeting and two extraordinary general meetings during the reporting period, ensuring compliance with legal requirements and protecting shareholder rights[83]. - The board of directors consists of five members, including two independent directors, and has established four specialized committees to enhance governance and oversight[84]. - The total remuneration for the board members and senior management during the reporting period amounted to 4.5176 million yuan[89]. - The company has maintained a stable management team with no changes in shareholding among directors and supervisors[89]. - The company has a diverse management background with members having experience in various sectors including finance and project management[90]. - The company has established specialized committees within the board, including an audit committee and a strategic committee[103]. Financial Position and Assets - The company's total assets amounted to RMB 1,671,235,752.66 in 2021, compared to RMB 1,632,143,258.27 in 2020, reflecting a growth of 2.4%[177]. - Total liabilities reached CNY 1,265,140,435.82, compared to CNY 669,327,720.34 in 2020, reflecting a substantial increase of around 89%[174]. - The company's total equity decreased to RMB 1,017,750,548.45 in 2021 from RMB 1,151,086,977.23 in 2020, a decline of 11.6%[177]. - The company has pledged 368,078,828.90 RMB of subsidiary net assets to secure a bank loan for acquiring 60% of Dongfang Huakang Medical Management Co., Ltd.[71]. - The company has engaged in cash asset management, with a total of ¥20,000,000 in bank fixed-term wealth management and ¥30,000,000 in structured deposits[153]. Strategic Initiatives and Future Outlook - The company plans to enhance brand marketing and product innovation to strengthen its market position in the health food sector[33]. - The company is implementing a dual-channel marketing strategy, combining online and offline sales, and targeting both B2B and B2C markets[35]. - The company plans to focus on expanding its market presence and investing in new technologies to drive future growth[196]. - The company expects net profits for 2022, 2023, 2024, and 2025 to be CNY 45 million, CNY 60 million, CNY 80 million, and CNY 80 million respectively, totaling CNY 245 million over five years[128]. Social Responsibility and Environmental Impact - The company has donated a total of 268,200 CNY to support rural revitalization projects, with specific contributions of 150,000 CNY to the Yanglouping Village project and 100,000 CNY to the Dongliuxi Village project[122]. - The company emphasizes environmental protection by adopting an ecological breeding model that reduces carbon emissions and promotes sustainable development[117]. - The company has released over 100 million high-quality fish fry to protect the aquatic ecological environment over the past decade[120].

Financial Performance - The company's operating revenue for 2022 was CNY 1,094,712,820.42, a decrease of 15.29% compared to CNY 1,292,312,436.98 in 2021[23] - The net profit attributable to shareholders of the listed company was a loss of CNY 71,495,117.40, an improvement of 60.31% from a loss of CNY 180,118,858.50 in the previous year[23] - The net cash flow from operating activities was CNY 97,866,143.08, showing a slight increase of 1.50% compared to CNY 96,420,908.67 in 2021[23] - Total assets at the end of 2022 were CNY 2,161,876,319.04, a decrease of 7.63% from CNY 2,340,424,356.56 at the end of 2021[23] - The net assets attributable to shareholders of the listed company decreased by 7.34% to CNY 879,723,654.23 from CNY 949,434,742.91 in 2021[23] - Basic earnings per share improved by 59.46% from -0.37 CNY in 2021 to -0.15 CNY in 2022[24] - Diluted earnings per share also increased by 59.46% from -0.37 CNY in 2021 to -0.15 CNY in 2022[24] - The weighted average return on equity improved by 9.38 percentage points from -17.2% in 2021 to -7.82% in 2022[24] - The company reported a net loss of CNY 219,125,049.68 in 2022, compared to a net loss of CNY 147,629,932.28 in 2021, indicating a worsening of approximately 48.4%[195] Business Operations - The company faced a decline in revenue from its main business, with a decrease of 15.51% in the revenue excluding non-main business income[23] - The company is focusing on health products and health services, aiming to upgrade to a comprehensive health industry[33] - The aquaculture division is enhancing brand marketing and optimizing product structure based on high-quality seedling breeding and ecological balance[33] - The company is committed to ecological aquaculture, promoting the production of safe and healthy organic freshwater products[33] - The company plans to continue expanding its sales channels and improving its product structure in the health sector[33] - The revenue from frozen and chilled products (including prepared dishes) increased by approximately 13% year-on-year in 2022[34] - The company has established a pre-prepared dish industrial park with a total area of 46,700 square meters, including a cold storage area of over 1,900 square meters, expected to increase production capacity by 15,700 tons[34] - The company has adjusted its product structure to focus on the development of sauce-flavored liquor, with an increasing proportion of mid-range and high-end series liquor products[37] - The health medical service division has implemented a quality management monitoring system to enhance medical service quality and improve hospital reputation[38] - The company has established a rehabilitation hospital and nursing home in Hangzhou, which officially opened in August 2022, aligning with national health strategies[40] Market Trends and Opportunities - The pre-made dishes market in China is expected to exceed 800 billion yuan by 2025, with the pre-made dish market for sauerkraut fish projected to reach 1.69 billion yuan, highlighting the growth potential in the aquatic pre-made dish sector[46] - The aquatic pre-made dish market is becoming a new growth point for the aquatic industry, driven by changing consumer habits and the demand for convenient, healthy food options[46] - The number of rehabilitation medical discharges in China reached 4.42 million in 2021, with a five-year compound growth rate of 8.81%, indicating a growing demand for rehabilitation services[50] - The Chinese rehabilitation medical market is expected to exceed 220 billion yuan by 2025, driven by an aging population and increasing rehabilitation needs[50] Corporate Governance - The company has established a governance structure that includes a board of directors with 5 members, including 2 independent directors[91] - The company held 9 board meetings and 5 supervisory meetings during the reporting period[92] - The company held 1 annual general meeting and 2 extraordinary general meetings during the reporting period, with a total of 22 proposals reviewed and approved[94] - The total pre-tax remuneration for the chairman and general manager was CNY 798,700, while the vice chairman received CNY 332,200[96] - The company has maintained a consistent management team with no changes in shareholding reported for the year[96] Financial Health and Investments - The company's cash and cash equivalents decreased by 32.10% to ¥231,449,101.93, primarily due to the repayment of short-term loans[78] - The company reported a significant reduction in short-term borrowings by 16.04% to ¥263,806,070.52, reflecting repayment efforts[79] - The company has engaged in bank wealth management with a total amount of 94,260,000 RMB, with no overdue amounts[166] - The company has a rental payment obligation totaling 342,873,165.3 RMB, after deducting payments made in 2021 and 2022[163] - The company has ongoing guarantees for rental payments amounting to 313,574,275.7 RMB for two hospitals[162] Research and Development - Research and development expenses increased by 160.99% to CNY 947.66 thousand, reflecting a focus on innovation[61] - Total R&D investment accounted for 0.08% of operating revenue, with all R&D expenses being expensed rather than capitalized[74] - The company has implemented a diversified training program to enhance employee skills and core competitiveness, resulting in a significant increase in the number of employees obtaining intermediate and senior professional titles in 2022[120] Social Responsibility - The company contributed a total of CNY 25.64 million to various charitable projects, including CNY 17 million in cash donations and CNY 8.64 million in material donations[129] - The total donation for rural revitalization and poverty alleviation projects amounted to CNY 32.65 million, with specific contributions of CNY 20 million to Yanglouping Village and CNY 10 million to Dongxi West Village[130] - The company has actively participated in social responsibility initiatives, including environmental protection and community support[128] Strategic Changes and Future Plans - The company has acknowledged potential risks in its future plans and development strategies, advising investors to be cautious[6] - The company plans to issue non-public A-shares in 2022, with a feasibility analysis for the use of raised funds[108] - The company is focusing on new product development and technological advancements to drive future growth[171] - The overall financial performance indicates a positive outlook for the upcoming fiscal year, with strategic initiatives in place[171]

证券代码：600257 证券简称：大湖股份 公告编号：2023-020 大湖水殖股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 关于召开 2022 年度业绩说明会的公告 重要内容提示： 会议召开时间：2023 年 06 月 09 日(星期五)下午 15:00-16:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址:http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络视频和网络文字互动 投资者可于 2023 年 06 月 02 日(星期五)至 06 月 08 日(星期 四)16:00 前登录上证路演中心网站首页点击"提问预征集"栏 目或通过公司邮箱 925286482@qq.com 进行提问。公司将在说明 会上对投资者普遍关注的问题进行回答。 大湖水殖股份有限公司（以下简称"公司"）已于 2023 年 4 月 26 日披露公司 2022 年年度报告，为便于广大投资者更全面深入地了 解公司 2022 年度经营成果、财务状况，公 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 250,086,468.74, representing a year-on-year increase of 14.19%[4] - The net profit attributable to shareholders was a loss of CNY 9,137,404.94, which is a deterioration of 30.75% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was a loss of CNY 11,199,650.32, reflecting a decline of 25.43% year-on-year[4] - The net loss for Q1 2023 was CNY 1,962,582.84, compared to a net loss of CNY 1,000,000.00 in Q1 2022, indicating a worsening of financial performance[18] - The net profit for Q1 2023 was -7,235,139.22 RMB, compared to -13,072,794.39 RMB in Q1 2022, showing an improvement of approximately 44.5% year-over-year[19] - The total operating profit for Q1 2023 was -1,087,630.25 RMB, a significant decrease from -8,458,869.94 RMB in the same period last year[19] - The company reported a total revenue from sales of goods and services of 286,790,049.11 RMB, up from 265,275,237.37 RMB in Q1 2022, representing a growth of approximately 8.5%[21] - The basic and diluted earnings per share for Q1 2023 were both -0.0190 RMB, an improvement from -0.0274 RMB in Q1 2022[20] - The total comprehensive income attributable to the parent company for Q1 2023 was -9,137,404.94 RMB, an improvement from -13,194,146.45 RMB in Q1 2022[20] Cash Flow and Assets - The net cash flow from operating activities was CNY 9,706,948.72[4] - The company reported a significant decrease in cash flow from investment activities, down 64.59% due to no financial investments made during the period[6] - Cash flow from operating activities generated a net inflow of 9,706,948.72 RMB, a recovery from a net outflow of -57,552,807.28 RMB in Q1 2022[22] - The net cash flow from financing activities was 11,351,611.04 RMB, a turnaround from a net outflow of -36,112,966.30 RMB in Q1 2022[22] - The company's cash and cash equivalents as of March 31, 2023, amounted to CNY 245,208,241.35, compared to CNY 231,449,101.93 at the end of 2022, representing a growth of 5.5%[13] - The cash and cash equivalents at the end of Q1 2023 were 244,771,151.84 RMB, compared to 215,064,915.34 RMB at the end of Q1 2022, indicating an increase of about 13.8%[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,159,956,485.13, a slight decrease of 0.09% from the end of the previous year[5] - The total assets of the company as of March 31, 2023, were CNY 2,159,956,485.13, slightly down from CNY 2,161,876,319.04 at the end of 2022[15] - The total liabilities increased to CNY 1,166,712,784.79 as of March 31, 2023, compared to CNY 1,160,504,202.31 at the end of 2022, reflecting a rise of 0.5%[15] - Shareholders' equity attributable to the parent company was CNY 869,692,972.12, down 1.14% from the previous year-end[5] - The company reported a decrease in retained earnings, with a balance of CNY -228,262,454.62 as of March 31, 2023, compared to CNY -219,125,049.68 at the end of 2022[15] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 52,169[8] - The largest shareholder, Tibet Hongshan Technology Development Co., Ltd., held 21.74% of the shares, with 51,340,000 shares pledged[8] Operating Costs and Expenses - Total operating costs for Q1 2023 were CNY 252,049,050.98, up from CNY 227,658,563.61 in Q1 2022, reflecting a year-over-year increase of 10.7%[18] - The company incurred total operating expenses of 298,300,099.05 RMB in Q1 2023, down from 340,396,564.94 RMB in Q1 2022, reflecting a reduction of approximately 12.4%[22] - Research and development expenses for Q1 2023 were CNY 214,447.17, significantly higher than CNY 57,003.97 in Q1 2022, marking an increase of 276.5%[18] Other Financial Metrics - The weighted average return on equity was -1.04%, an increase of 0.36 percentage points compared to the previous year[4] - The company recorded an asset disposal loss of 2,440.00 RMB in Q1 2023, compared to a loss of 17,431.33 RMB in Q1 2022[19] - Accounts receivable increased to CNY 148,235,179.44 as of March 31, 2023, from CNY 128,934,683.31 at the end of 2022, indicating a rise of 14.9%[13] - Inventory decreased to CNY 493,205,864.19 as of March 31, 2023, down from CNY 520,826,478.84 at the end of 2022, a decline of 5.3%[13]

Financial Performance - The company's operating revenue for 2022 was CNY 1,094,712,820.42, a decrease of 15.29% compared to CNY 1,292,312,436.98 in 2021[23] - The net profit attributable to shareholders of the listed company was a loss of CNY 71,495,117.40, an improvement of 60.31% from a loss of CNY 180,118,858.50 in the previous year[23] - The net cash flow from operating activities was CNY 97,866,143.08, showing a slight increase of 1.50% compared to CNY 96,420,908.67 in 2021[23] - Total assets at the end of 2022 were CNY 2,161,876,319.04, down 7.63% from CNY 2,340,424,356.56 at the end of 2021[23] - The net assets attributable to shareholders of the listed company decreased by 7.34% to CNY 879,723,654.23 from CNY 949,434,742.91 in 2021[23] - Basic earnings per share improved by 59.46% from -0.37 CNY in 2021 to -0.15 CNY in 2022[24] - Diluted earnings per share also increased by 59.46% from -0.37 CNY in 2021 to -0.15 CNY in 2022[24] - The weighted average return on equity improved by 9.38 percentage points from -17.2% in 2021 to -7.82% in 2022[24] - The company reported a net loss of CNY 219,125,049.68 for the year, compared to a loss of CNY 147,629,932.28 in the previous year, indicating a worsening of approximately 48.4%[192] - The company reported a total revenue of $1.06 billion from offline sales, down 15.80% year-over-year, with a gross margin of 23.19%, decreasing by 3.94 percentage points[64] Revenue Breakdown - The company faced a decrease in revenue from its main business, with a reported figure of CNY 1,085,246,159.37, down 15.51% from CNY 1,284,524,215.94 in the previous year[23] - Total revenue for Q1 2022 was 219,017,105.58 CNY, while Q2 was 320,603,898.69 CNY, Q3 was 288,475,793.47 CNY, and Q4 was 266,616,022.68 CNY[26] - The total revenue from the medical services segment was $222.95 million, with a gross margin of 28.26%, reflecting a year-over-year increase of 3.66%[64] - The total revenue from online sales was $23.38 million, with a gross margin of 39.71%, showing a slight decrease of 0.32% year-over-year[64] - The company’s total revenue from the central-south region was $732.74 million, down 21.99% year-over-year, with a gross margin of 23.55%, a decrease of 1.26 percentage points[64] - The total revenue from the east China region was $279.79 million, reflecting a year-over-year increase of 14.18%, with a gross margin of 25.68%, down 13.94 percentage points[64] Cost Management - The company reported a 10.84% reduction in operating costs, totaling CNY 835,395,069.46[61] - The company reported a significant decrease in selling expenses, which fell to CNY 59,120,971.80 in 2022 from CNY 95,535,225.90 in 2021, a reduction of approximately 38%[200] - Total operating costs for 2022 were CNY 1,100,011,040.37, down from CNY 1,244,399,571.64 in 2021, reflecting a reduction of about 11.6%[199] Investments and R&D - Research and development expenses increased by 160.99%, reaching CNY 947,656.36[61] - Research and development expenses increased to CNY 947,656.36 in 2022 from CNY 363,103.11 in 2021, representing a growth of approximately 161.5%[200] Governance and Compliance - The company maintained a robust governance structure, adhering to relevant laws and regulations to protect shareholder rights[88] - The board of directors convened 9 meetings, ensuring compliance with governance standards and effective oversight[89] - The company held 1 annual and 2 temporary shareholder meetings during the reporting period, with all resolutions passed without any objections[90] Market and Strategic Initiatives - The company focused on optimizing product structure and enhancing sales channels to support its health product and health service strategy[33] - The aquaculture division emphasized ecological breeding and sustainable practices to produce high-quality organic freshwater products[33] - The company aims to upgrade and transform into a comprehensive health industry by integrating health products and services[33] - The company has established a pre-prepared dish industrial park with a total area of 46,700 square meters, including a cold storage area of over 1,900 square meters, expected to increase production capacity by 15,700 tons[34] Employee and Management - The total number of employees in the parent company is 211, while the main subsidiaries employ 1,480, resulting in a total of 1,691 employees[112] - The total remuneration for all directors, supervisors, and senior management was 4.286 million yuan[102] - The company emphasizes the importance of grassroots employee compensation, directing performance rewards primarily to frontline staff[114] Environmental and Social Responsibility - The company invested 263.49 million yuan in environmental protection during the reporting period[122] - The company has contributed a total of 32.65 million yuan to poverty alleviation and rural revitalization projects, including 20 million yuan to support a specific village[127] - The company is committed to ecological sustainability in its operations, aligning with government initiatives for high-quality green development[169] Acquisitions and Partnerships - The company acquired 60% equity in Dongfang Huakang for a total cash consideration of 250 million RMB, including 50 million RMB for 8% equity and 200 million RMB for 32% equity, along with a capital increase of 12.5 million RMB[133] - The company and its subsidiary invested RMB 27 million each to hold 90% equity in two newly established hospitals, Shanghai Jinxian Rehabilitation Hospital and Shanghai Fengxiang Nursing Home[150] Future Outlook - The company has plans for market expansion and new product development in the upcoming fiscal year[168] - The overall financial performance indicates a stable growth trajectory, with a focus on enhancing user engagement and product offerings[168]

2022 年第三季度报告 证券代码：600257 证券简称：大湖股份 大湖水殖股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比 上年同期增减变动 | | --- | --- | --- | --- | --- | | | | 增减变动幅度(%) | | | | | | | | 幅度(%) | | 营业收入 | 288,475,793.47 | -17.39 | 828,096,797.74 | -11.52 | | 归属 ...

证券代码：600257 证券简称：大湖股份 公告编号：2022-048 大湖水殖股份有限公司 关于参加 2022 年湖南辖区上市公司 投资者网上集体接待日活动的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，使广大投资者能更深入 全面地了解大湖水殖股份有限公司（以下简称"公司"）情况，公 司将参加由中国证券监督管理委员会湖南监管局、湖南省上市公 司协会和深圳市全景网络有限公司联合举办的"湖南辖区上市公 司投资者网上接待日活动"，现将有关事项公告如下： 本次投资者网上接待日活动将通过深圳市全景网络有限公 司提供的互联网平台举行，投资者可以登录"全景·路演天下" 网站（http://rs.p5w.net），参与公司本次投资者网上接待日活 动，活动时间为 2022 年 9 月 29 日（星期四）下午 14:00 至 17:00， 下午 15:30 开始上市公司与投资者网上互动环节。 届时公司董事会秘书及证券事务代表将通过网络文字交流 形式与投资者进行沟通与交流。欢迎广大投资者积极参与。 ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥539,621,004.27, a decrease of 8.02% compared to ¥586,683,773.82 in the same period last year[18]. - The net profit attributable to shareholders of the listed company was a loss of ¥14,233,928.27, a decline of 282.73% from a profit of ¥7,789,781.05 in the previous year[18]. - The net cash flow from operating activities was a negative ¥103,974,462.55, worsening from a negative ¥27,929,507.43 in the same period last year, representing a decline of 272.27%[18]. - Basic earnings per share for the first half of 2022 were -¥0.0301, a decrease of 285.8% compared to ¥0.0162 in the same period last year[19]. - The weighted average return on net assets was -1.54%, a significant decline from 0.67% in the previous year[19]. - The total revenue for the first half of 2022 was approximately ¥56,544,557.23, showing a significant increase compared to the previous period[84]. - The net profit for the first half of 2022 was a loss of ¥12,408,701.60, compared to a profit of ¥17,357,586.26 in the same period of 2021[116]. - The total operating revenue for the first half of 2022 was ¥539,621,004.27, a decrease of 8.01% compared to ¥586,683,773.82 in the same period of 2021[115]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,255,354,603.97, down 3.63% from ¥2,340,424,356.56 at the end of the previous year[18]. - The net assets attributable to shareholders of the listed company decreased by 1.50% to ¥935,200,814.65 from ¥949,434,742.91 at the end of the previous year[18]. - The company's total assets as of June 30, 2022, amounted to ¥1,683,889,870.37, an increase from ¥1,671,235,752.66 at the end of 2021[113]. - Total liabilities as of June 30, 2022, were ¥654,938,308.96, slightly up from ¥653,485,204.21 at the end of 2021[113]. - The total liabilities decreased from CNY 1,265,140,435.82 to CNY 1,194,085,000.82, a decline of about 5.59%[107]. Cash Flow and Investments - The company's cash and cash equivalents decreased by 60.21%, from CNY 340,891,113.94 to CNY 135,648,767.86, primarily due to significant investments in two new rehabilitation hospitals in Hangzhou[49]. - The company reported a net cash outflow from investing activities of CNY 36,720,694.99, an improvement of 63.91% compared to the previous year's outflow of CNY 101,743,149.03[49]. - The company received RMB 150 million in borrowings during the first half of 2022, compared to RMB 390.5 million in the same period of 2021, indicating a decrease in financing activities[124]. - The net cash flow from investing activities was -¥15,176,732.76, compared to -¥151,321,948.85 in the previous period, indicating a significant reduction in cash outflow[129]. Business Segments and Operations - The main business segments include health product production and sales, as well as health medical service management, focusing on the synergy between these two areas[23]. - The company operates multiple rehabilitation and nursing institutions, targeting elderly, children, and patients, with a comprehensive service offering in rehabilitation care[26]. - The revenue from the aquaculture segment accounted for 57% of total revenue in the first half of 2022[43]. - The health medical service segment's revenue accounted for 19% of total revenue in the first half of 2022[45]. - The company is committed to upgrading its business model towards a comprehensive health industry, focusing on health products and services[45]. Market Trends and Demand - The demand for ready-to-eat seafood products is rapidly increasing, with the market expected to exceed RMB 800 billion by 2025, and the sauerkraut fish segment projected to reach RMB 1.69 billion[31]. - The rehabilitation medical market in China is expected to surpass RMB 220 billion by 2025, driven by an aging population and increasing rehabilitation needs[35]. - The total area of aquaculture in China has shown a declining trend, with a 1.12% decrease in freshwater aquaculture area in 2022, yet the overall production of aquatic products remains stable[28]. Research and Development - The company has made significant advancements in research and innovation, including the development of key technologies for freshwater fish deep processing, which have received provincial and national awards[38]. - Research and development expenses dropped significantly by 93.13%, from CNY 2,855,049.36 to CNY 196,052.02[49]. - The company is focused on ecological breeding models and has made progress in breeding disease-resistant fish varieties, ensuring high-quality fish production[38]. Corporate Governance and Shareholding - The total number of ordinary shareholders as of the end of the reporting period was 65,349[94]. - The largest shareholder, Tibet Hongshan Technology Development Co., Ltd., holds 104,631,211 shares, accounting for 21.74% of the total shares[96]. - The company has not reported any stock buyback accounts among the top ten shareholders[97]. Strategic Initiatives - The company has initiated the operation of two new rehabilitation hospitals in Hangzhou as part of its market expansion strategy[50]. - The company plans to invest CNY 276 million in a prepared food processing project, with CNY 220 million allocated for the construction of a processing center and base, expected to increase production capacity by 15,700 tons[42]. - The company is enhancing its marketing channels by integrating online and offline sales, including direct sales, agency, group buying, and e-commerce platforms[44]. Sustainability and Ecological Practices - The company emphasizes ecological and sustainable development in aquaculture, aligning with national policies promoting green practices in the industry[27]. - The company has adopted an ecological breeding model for fish farming, focusing on low energy consumption and pollution, aligning with national green development initiatives[62]. - The company is focusing on ecological aquaculture and has adopted strategies for sustainable development, including the use of lake biological governance and nutrient control technologies[41].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 219,017,105.58, representing a decrease of 18.21% compared to the same period last year[6]. - The net profit attributable to shareholders of the listed company was a loss of CNY 13,194,146.45, with a diluted earnings per share of -0.0274 yuan[7]. - The net cash flow from operating activities was -CNY 57,552,807.28, a significant decline of 90.97% year-on-year[6]. - Total operating revenue for Q1 2022 was ¥219,017,105.58, a decrease of 18.2% compared to ¥267,767,402.54 in Q1 2021[23]. - Net profit for Q1 2022 was a loss of ¥13,072,794.39, compared to a profit of ¥9,710,054.34 in Q1 2021, representing a significant decline[24]. - The company reported a net loss of RMB 160,824,078.73 for the period, compared to a loss of RMB 147,629,932.28 in the previous period, indicating a worsening of approximately 8.5%[20]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,258,071,834.82, down 3.52% from the end of the previous year[7]. - The company's current assets totaled RMB 1,006,157,717.97, down from RMB 1,091,283,500.44, indicating a decrease of about 7.8%[18]. - Cash and cash equivalents were reported at RMB 215,896,512.45, significantly lower than RMB 340,891,113.94 from the previous year, representing a decline of approximately 36.7%[18]. - The company's total liabilities decreased to RMB 1,197,466,324.47 from RMB 1,265,140,435.82, marking a reduction of about 5.3%[20]. - Total assets decreased from CNY 1,671,235,752.66 to CNY 1,618,102,028.53, a decline of approximately 3.2%[32]. - Total liabilities decreased from CNY 653,485,204.21 to CNY 611,689,352.32, a reduction of approximately 6.4%[32]. Cash Flow - The company reported a net cash outflow from operating activities of ¥57,552,807.28 in Q1 2022, compared to an outflow of ¥30,137,168.38 in Q1 2021[27]. - In Q1 2022, the company's net cash flow from operating activities was ¥10,710,332.40, a significant improvement from a net outflow of ¥37,919,803.99 in Q1 2021[38]. - The company reported a net cash flow from investing activities of -¥14,977,147.98, an improvement from -¥154,744,533.02 in Q1 2021[39]. - The net cash flow from financing activities was -¥33,723,973.89, compared to a positive net flow of ¥177,735,737.48 in Q1 2021[39]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 84,451[13]. - The largest shareholder, Tibet Hongshan Technology Development Co., Ltd., held 21.74% of the shares, with 51,340,000 shares pledged[14]. Expenses and Investments - The company incurred a significant increase in tax expenses, totaling ¥4,937,603.91 in Q1 2022, compared to ¥644,178.31 in Q1 2021[24]. - Research and development expenses decreased to ¥57,003.97 in Q1 2022 from ¥265,346.06 in Q1 2021, indicating a reduction in investment in innovation[23]. - The company reported a loss from investment activities of ¥361,084.60 in Q1 2022, contrasting with a gain of ¥386,943.97 in Q1 2021[23]. - Total cash inflow from investment activities was ¥62,070,592.22 in Q1 2022, compared to ¥610,048.23 in Q1 2021, reflecting a decrease in investment returns[28].

Financial Performance - The company's operating revenue for 2021 was approximately CNY 1.29 billion, representing a 37.99% increase compared to CNY 936.52 million in 2020[21]. - The net profit attributable to shareholders for 2021 was a loss of approximately CNY 180.12 million, a decrease of 4,417.79% compared to a profit of CNY 4.17 million in 2020[22]. - The net cash flow from operating activities for 2021 was approximately CNY 96.42 million, a significant improvement of 387.10% compared to a negative cash flow of CNY 33.58 million in 2020[22]. - Total assets at the end of 2021 were approximately CNY 2.34 billion, an increase of 18.89% from CNY 1.97 billion at the end of 2020[22]. - The company's net assets attributable to shareholders decreased by 18.4% to approximately CNY 949.43 million at the end of 2021, down from CNY 1.16 billion at the end of 2020[22]. - The basic earnings per share for 2021 was -0.37 RMB, a decrease of 4,352.87 percentage points compared to 2020[23]. - The weighted average return on net assets was -17.20%, down 17.56 percentage points from the previous year[23]. - The company reported a significant loss in the fourth quarter, with a net profit attributable to shareholders of -200.37 million RMB[27]. - The company reported a net profit of ¥3,864,000 from Oriental Huakang Medical Management Co., Ltd. for the reporting period[77]. - The company reported a total loss of -180,118,858.50, which reflects a decline in financial performance[198]. Revenue Segmentation - The revenue from the aquaculture segment accounted for 58.65% of the total, representing a year-on-year growth of 24.36%, with frozen aquatic products sales increasing by 280.16%[35]. - The health liquor segment's revenue share was 10.86%, showing a significant year-on-year increase of 49.95%[36]. - The health medical services segment's revenue share reached 16.74%, with a remarkable year-on-year growth of 530.07%[38]. Business Strategy and Development - The company plans to upgrade its business model towards a comprehensive health industry, integrating health products and services[33]. - The company is focusing on the development of a "medical, nursing, and rehabilitation" integrated model in its health services[38]. - The company is investing in the establishment of rehabilitation hospitals and nursing homes to enhance its presence in the health service industry[38]. - The company is adapting to changing consumer preferences by increasing the sales proportion of frozen and ready-to-eat products[35]. - The company is implementing a brand marketing strategy focused on key regions such as the Greater Bay Area and Yangtze River Delta[35]. - The company is enhancing its management capabilities and optimizing resource allocation to support business development[38]. Risk Management - The company reported no significant risks that could materially affect its operations during the reporting period[9]. - The company has not engaged in non-operating fund occupation by controlling shareholders or related parties[7]. - The company has not violated decision-making procedures for external guarantees[7]. - The company emphasizes the importance of investor awareness regarding potential risks in its future plans and strategies[6]. - The company faces competition risks from pond-cultured fish, which have higher yields compared to the company's naturally farmed fish[79]. - The company faces risks from food safety issues that could impact reputation and sales, and plans to enhance quality control and internal management systems[80]. - Rising operational costs, including labor and breeding expenses, pose a risk, and the company intends to mitigate this through refined management and brand enhancement strategies[80]. Corporate Governance - The company held 1 annual and 2 temporary shareholder meetings during the reporting period, with a total of 16 resolutions passed, including 1 special resolution[88]. - The total remuneration for the board members and senior management during the reporting period amounted to CNY 4.5176 million[90]. - The company has maintained a stable management team with no changes in shareholding among directors and supervisors[90]. - The company has a structured compensation decision-making process involving the board's remuneration committee and shareholder meetings[98]. - The company has a total of 6 specialized committees under the board, including the Audit Committee and the Strategic Committee[104]. Social Responsibility and Sustainability - The company actively engages in social responsibility, focusing on protecting the rights of shareholders, employees, and the environment[119]. - The company has donated a total of 268,200 CNY to support rural revitalization projects, with specific contributions of 150,000 CNY to the Yanglouping Village project and 100,000 CNY to the Dongliuxi Village project[123]. - The company has released over 100 million high-quality fish fry to protect the aquatic ecological environment over the past decade[121]. - The company adheres to an ecological farming model, promoting sustainable aquaculture practices that align with national green development initiatives[118]. Investment and Financial Management - The company has invested ¥20,000,000 in bank fixed-term wealth management products, with no overdue amounts[154]. - The company has allocated ¥30,000,000 to structured deposits, also with no overdue amounts[154]. - The company has invested ¥22,999,000 in corporate/retirement wealth management products, with a remaining balance of ¥20,000,000[154]. - The company has pledged its 60% equity stake in Oriental Huakang Medical Management Co., Ltd. as collateral for a bank loan of ¥368,078,828.90, with a loan term of 84 months at an interest rate of 4.65%[72]. Employee Management - The total number of employees in the parent company is 342, while the main subsidiaries employ 1,477, resulting in a total of 1,819 employees[107]. - The company emphasizes performance management and has implemented a performance evaluation system for subsidiaries, focusing on aligning employee compensation with company performance[108]. - The company maintains a moderate increase in employee wages, ensuring that the growth rate of employee income does not exceed the company's performance growth rate[109].